Objectives: To investigate the prescribing of systemic drugs for the treatment of acne in adolescents in the period 2005-15.
Introduction
Acne vulgaris (acne) is a chronic inflammatory disease that can persist into adulthood. The disease is caused by several interacting factors, such as overproduction of sebum (seborrhoea), colonization by Propionibacterium acnes, follicular hyperkeratosis and inflammation. 1 Most people are affected, particularly at the age 15-17 years; 2 about 15%-20% experience moderate to severe acne. 2 The choice of treatment for acne depends on the severity of the disease. [3] [4] [5] [6] For moderate to severe acne, systemic treatment with oral antibiotics (tetracyclines) in combination with topical retinoid and/or benzoyl peroxide is recommended. [3] [4] [5] [6] Isotretinoin is indicated if there is no response to the oral antibiotics. Treatment with combined oral contraceptives containing antiandrogen and oestrogen are recommended as an alternative therapy for women. Comparative studies on the efficacy of a particular treatment in relation to the others, or on the sequence of therapy, are scarce. 7 Treatment with systemic tetracyclines leads to 50%-70% reduction in the number of inflammatory lesions, but does not clear acne completely. 2, 3 Treatment response can be assessed after 6-8 weeks, 8 but it is recommended to continue treatment for a longer period of time to ensure efficient treatment. Although it is recommended to discontinue treatment with systemic tetracyclines after 3-6 months, [3] [4] [5] [6] Nagler et al. 9 reported an average treatment period with systemic antibiotics of 11 months. In addition to adverse effects, long-term use of systemic antibiotics has other harmful effects such as the development and spread of antibiotic resistance and disruption of the overall ecology of the gut microbiota. 10 It has been shown that it can take up to 4 years before the normal gut microbiota is re-established after a single antibiotic course of 7 days. 11 Disturbances of the skin microbiota have been associated with dermatological diseases such as acne, atopic dermatitis, rosacea and psoriasis. 12 Long-term use of antibiotics to treat acne has led to an increase in the levels of antibiotic-resistant P. acnes strains. 13 It is the use of antibiotics that drives the development of resistant bacterial strains. 14 Even if a patient does not have or develop treatment-resistant acne, the high selective pressure resulting from long-term use of systemic tetracyclines to treat acne will drive the development of resistant bacteria in the patient's gut and will also be of harm to other individuals due to the spread of resistant bacteria. A systematic review of antibiotic resistance in acne has highlighted the need for detailed studies on antibiotic use to treat acne, both to determine the length of treatment courses and whether there are differences between countries in the pattern of use. 13 A recent study on the management of acne in primary care in the UK concluded that there is lack of follow-up and also suboptimal treatment of acne patients. 15 The present work is, to our knowledge, the first population-based study of the use of systemic tetracyclines, isotretinoin and hormonal therapy in acne. The aim of the study was to investigate the prescribing patterns of systemic drug therapy for the treatment of acne in adolescents and young adults over an 11 year period with special focus on treatment with systemic tetracyclines.
Materials and methods

The Norwegian Prescription Database (NorPD)
Prescription data were obtained from the NorPD, which was established on 1 January 2004 and covers the entire population of Norway (5.1 million). 16 The database contains information on all prescribed drugs, reimbursed or not, dispensed at pharmacies to individual patients treated in ambulatory care. In Norway, drugs used for long-term treatment are dispensed for 3 months at a time. Prescriptions can be linked to the individual patient based on a unique identification code and the individual can be followed over time. Drug classification is based on the Anatomical Therapeutic Chemical (ATC) classification system. 17 Information about indication for treatment is not available for the drugs included in this study.
Study population
The study population consisted of all individuals in the age group 14-24 years who had received at least one dispensed prescription of a systemic tetracycline, isotretinoin and/or cyproterone and oestrogen (hormonal therapy) in the period 2005-15.
Definition of systemic drugs used to treat acne vulgaris
Systemic antibiotics used to treat acne vulgaris were defined as doxycycline (J01AA02), lymecycline (J01AA04), oxytetracycline (J01AA06) and tetracycline (J01AA07). For doxycycline, only prescriptions with a drug amount equivalent to 50 DDDs or more were included in the study. The DDD is a technical unit of measurement and is defined as 'the assumed average maintenance dose per day for a drug used for its main indication in adults'. 17 The main indication for doxycycline is treatment of respiratory tract infections. Since information about indications for antibiotic prescriptions is not available in the NorPD, a cut-off based on the number of DDDs dispensed had to be used in order to be able to distinguish between acute infections and long-term acne treatment. In order to exclude prescriptions that most likely were prescribed for respiratory tract infections (short treatment courses of 100-200 mg of doxycycline for 7-10 days corresponding to 7-20 DDDs), a cut-off of 50 DDDs was chosen. This 50 DDD cut-off is also based on the available package size of 50 tablets of 100 mg of doxycycline. Since the systemic antibiotics belong to the same class of antibiotics, the drugs were studied as one group ('tetracyclines'). Isotretinoin (D10BA01) is only indicated for treatment of moderate to severe acne vulgaris. Hormonal therapy for women was defined as use of cyproterone and oestrogen (G03HB01) and referred to as 'hormonal therapy' in the study.
The indications for use of cyproterone and oestrogen are treatment of moderate to severe acne and hirsutism.
Definitions and analytical strategy
Prevalence was defined as the number of individuals who had filled at least one prescription of tetracyclines, isotretinoin and/or hormonal therapy per year divided by the mean population of the specific age and gender. The mean population was retrieved from Statistics Norway. Incidence (new users) was defined as the number of individuals who had filled at least one prescription of tetracyclines, isotretinoin and/or hormonal therapy per year and who had not filled such a prescription during the previous 12 months divided by the mean population of the specific age and gender. A treatment course was defined as the period covering all filled prescriptions of the same drug with less than 365 days between the dispensing dates. If the gap between two filled prescriptions of the same drug was more than 365 days, the second filled prescription was considered as the start of a new treatment course. The reason for choosing a 365 day break between courses was to include relapses of the disease within the same treatment course to estimate the total duration of treatment for one acne episode. Duration of treatment was defined as the total number of DDDs per treatment course. For all drugs in this study, the assigned DDD corresponds well to the actual dosage used for treatment of acne vulgaris, i.e. the number of DDDs can be used as a proxy for the number of days of treatment. Prescriber's specialty was defined in accordance with hierarchical categories (in relation to acne treatment): (i) dermatology specialist; (ii) general practitioner specialist; (iii) other specialty; and (iv) no specialty or under training for a specialty (a prescriber with more than one specialty was considered to belong to the highest hierarchical category). Naive users of systemic drug therapy was defined according to the first filled prescription (start of treatment) in the period 2008-15 irrespective of drug group (tetracyclines, isotretinoin or hormonal therapy) with no filled prescriptions of any of the drug groups during the previous 48 months. Switch of treatment was analysed for naive users of tetracyclines who switched to isotretinoin during the same treatment course. If an individual had filled prescriptions of tetracyclines and isotretinoin during the same treatment course, the total number of DDDs of tetracyclines dispensed before the first filled prescription of isotretinoin was calculated to examine the duration of treatment with tetracyclines before a switch to isotretinoin treatment. The individuals were followed-up until the end of 2015. Data analysis was conducted using STATA version 14 (StataCorp, TX, USA).
Ethics
The study was approved by the Norwegian Institute of Public Health. Approval from the regional committees for medical and health research ethics in Norway was not required according to the Norwegian Health Registry Act. No informed consent was obtained since the study was based on secondary data from a nationwide register.
Results
Increase in prevalence and incidence rate of systemic drug therapy in the period 2005-15
The study population consisted of 144 220 individuals in the age group 14-24 years who had received at least one dispensed prescription of a systemic tetracycline, isotretinoin and/or hormonal therapy in the period 2005-15. In this period, 111 761 individuals filled at least one prescription of tetracyclines, 32 085 individuals filled at least one prescription of isotretinoin and 39 562 Systemic drug therapy for treatment of acne JAC individuals filled at least one prescription of drugs used for hormonal therapy. For tetracyclines, the prevalence in women increased from 1.6% in 2005 to 2.7% in 2015, and in men from 2.0% to 2.2% ( Figure 1 ). In the period 2005-11, the most commonly prescribed tetracycline was tetracycline (J01AA07) followed by lymecycline (J01AA04) ( Figure S1 , available as Supplementary data at JAC Online). In the period 2012-15, lymecycline (J01AA04) was the most commonly prescribed tetracycline ( Figure S1 ). For isotretinoin the prevalence in women increased from 0.1% to 1.0%, and in men from 0.3% to 1.0%. Since 2007 there has been a decrease in the prevalence of hormonal therapy for women, from 2.8% in 2007 to 2.1% in 2015. The incidence rate of tetracyclines, isotretinoin and hormonal therapy followed the same pattern as the prevalence of use of these drugs ( Figure S2 ).
Prevalence of use of tetracyclines per gender and age in the period 2005-15
The most frequent users of tetracyclines throughout the study period were 17-year-old men ( Figure 2 and Table S1 ). In the period 2005-15, there was a greater increase in the prevalence of use of tetracyclines among men under 18 years of age compared with men aged 18 years and above. Among women, tetracycline use was most frequent at 17 years of age, and more women than men were treated when they reached their twenties. The incidence of use of tetracyclines according to age followed the same pattern as the prevalence of use of the drugs (Table S2) .
Prescription by prescriber's specialty
In the period 2005-15, 54% of filled tetracycline prescriptions were prescribed by general practitioner specialists, while 24% and 19% of the prescriptions were prescribed by dermatology specialists and physicians with no specialty or under training for specialty, respectively. The majority (89%) of filled isotretinoin prescriptions were prescribed by dermatology specialists, while 4% and 6% of the prescriptions were prescribed by general practitioner specialists and physicians with no specialty or under training for specialty.
Tetracyclines were most often prescribed to naive users of systemic acne therapy A naive user of systemic acne therapy was defined according to the first filled prescription (start of treatment) in the period 2008-15 irrespective of drug group (tetracyclines, isotretinoin or hormonal therapy) with no filled prescriptions of any of the drug groups during the previous 48 months. In 2015, approximately 47% of the users among men and 39% of the female users in the 14-24 year age group were naive users of systemic acne therapy (Table S3) . Of these, 89% of the men and 72% of the women were first prescribed tetracyclines for treatment of acne ( Figure S3 ). As shown in Figure S3 , tetracyclines were most often prescribed to naive users of systemic acne therapy in the period 2008-15. Isotretinoin was increasingly prescribed to naive users for both men and women. For men, the proportion of individuals treated with isotretinoin with 
Treatment with tetracyclines only, compared with treatment with tetracyclines and switch to isotretinoin
The prescription pattern of naive users of tetracyclines was further analysed to determine how many continued with tetracyclines only compared with how many switched to isotretinoin during the same treatment course. A switch from tetracyclines to isotretinoin occurred in 20% of the treatment courses given to men and in 10% of the treatment courses given to women. When comparing the total number of DDDs of tetracyclines dispensed per treatment course for individuals with no switch to isotretinoin and for individuals that switched to isotretinoin during the same treatment course, men and women followed the same pattern ( 19 In our data we found a slight decrease in the prevalence and incidence of use of tetracyclines from 2012 in men and from 2014 in women. However, more data are needed in order to see whether this is a steady decrease over time. In the period 2005-15 we observed a shift in the type of tetracycline most commonly prescribed. In the beginning of the period tetracycline (J01AA07) was most often prescribed followed by lymecycline (J01AA04), but since 2012 lymecycline was most often prescribed. A shift to lymecycline over time was also observed in a study on the management of acne in primary care in the UK. 15 In adolescence, more men than women were treated with systemic tetracyclines, while more women than men were treated with tetracyclines in their twenties. This finding fits well with the prevalence of the disease in men and women according to age. 20, 21 We also found that the increase in use of systemic tetracyclines observed in the study period was greater for men below 18 years of age compared with men aged 18 years and above, indicating that treatment with systemic tetracyclines is initiated at an earlier age in men. Previous studies have shown that acne is less accepted by women than men, 22, 23 and that women in every age group consult more frequently than men. 15 The change in the onset of treatment with systemic tetracyclines towards an earlier age in men might indicate that men are increasingly more willing to seek treatment at an earlier age.
We found that systemic tetracyclines were most commonly prescribed to naive users of systemic acne therapy, both in men and women. In women, the decreased use of hormonal therapy in naive users was mainly replaced by an increased use of tetracyclines. Isotretinoin was more often prescribed to men, both to naive users of systemic acne therapy and to individuals who switched from tetracyclines to isotretinoin during the same treatment course. More frequent use of isotretinoin among men is due to the teratogenic effects of the drug, which possibly make women, and also prescribers, more reluctant to use the drug for treatment of acne.
It is not recommended to use systemic tetracyclines for more than 3 months to treat acne. 3 The average duration of tetracycline treatment for those that used tetracyclines only was 3.3 months in men and 2.8 months in women, corresponding well with the treatment guidelines. Both men and women who switched to isotretinoin used tetracyclines for 1 month longer compared with men and women who only used tetracyclines. This finding was surprising since one would expect that patients with more severe acne would switch to isotretinoin at an earlier stage.
Extended exposure to antibiotics (on average approximately 11 months) before a switch to isotretinoin was also observed in the period 2005-14 in a study by Nagler et al. 9 This is almost three times longer than what we observed in our study. The study by Nagler et al. 9 was conducted at a single medical centre and included 137 patients, and is not representative of the whole population. Unlike our study, they had access to diagnosis codes, The total number of DDDs of tetracyclines per treatment course. If there was a switch from tetracyclines to isotretinoin during the same course, the total number of DDDs dispensed before the first filled prescription of isotretinoin was calculated.
b Individuals who were first prescribed tetracyclines in the period 2008-14 and had no filled prescriptions of tetracyclines, hormonal therapy or isotretinoin in the previous 48 months (naive users of tetracyclines). The women included were naive users of tetracyclines, and had never filled any prescriptions of hormonal therapy throughout the study period. The individuals were followed-up until the end of 2015. c Only tetracyclines were dispensed per treatment course. d Switch from tetracyclines to isotretinoin during the same treatment course. Systemic drug therapy for treatment of acne JAC which enabled inclusion of severe acne cases only. In our study, diagnosis codes were lacking and we studied the whole population, which means that less severe cases were also included. Furthermore, we studied the mean duration of treatment with antibiotics per treatment course, whereas Nagler et al. 9 studied the total duration of treatment per patient history. A study by Lee et al. 24 also reported on the duration of antibiotic use per treatment course. They studied data from the MarketScan Commercial Claims and Encounters database in the period 2008-10, and found an average duration of antibiotic treatment of 129 days, which fits well with our results for patients that switched to isotretinoin. For patients who only used tetracyclines during a treatment course, we found an average duration of treatment of 92 days for men and women when excluding courses of less than 25 DDDs ( Table 1 ). The differences observed between the studies show that country-specific studies are important when studying the duration of systemic treatment of acne, since both treatment traditions and the levels of antibiotic use in general can differ in different settings. 25, 26 We found that 24% of filled tetracycline prescriptions were prescribed by dermatology specialists, meaning that general practitioner specialists and physicians with no specialty or under training for a specialty accounted for approximately three-quarters of the tetracycline prescriptions. These numbers show that prescribing of tetracyclines to treat acne is to a large extent driven by physicians other than dermatology specialists. One reasonable explanation for this is that patients need to be referred to a dermatology specialist, i.e. they have much easier access to general practitioner specialists and physicians with no specialty. Also, the treatment recommendation states that systemic tetracyclines should be the first-line treatment of moderate to severe acne, which means that patients are probably first referred to a dermatology specialist when treatment with tetracyclines fails.
In Norway, isotretinoin treatment can only be initiated by specialists in dermatology. In order to reduce the long-term use of antibiotics driven by prescribing in primary care it is important that patients with severe acne are identified and referred to a dermatology specialist at an earlier stage. It is also of importance to consider whether more patients should be treated with isotretinoin only, and not tetracyclines, since it has been shown that treatment with isotretinoin is more efficient than treatment with tetracyclines. 27, 28 A change in treatment guidelines to isotretinoin as firstline treatment of severe acne must be considered with great caution due to the teratogenic effect of the drug. Such a change might well make treatment less available to patients since they must be referred to a specialist in dermatology to initiate treatment. One way to increase access to care could be to allow primary care physicians to prescribe isotretinoin.
Strengths and limitations
This study is based on data from a population-based register that covers all prescriptions of systemic tetracyclines, isotretinoin and hormonal therapy given to outpatients throughout the study period. Information on diagnosis is lacking for the drugs studied here, which might have led to misclassification of treatment as systemic acne therapy. Even though the study population is 14-24 years of age, the period when acne is most common, we cannot rule out other indications for long-term use of systemic tetracyclines (e.g. rosacea and neuroborreliosis). The main indication of use of doxycycline is respiratory tract infections, and although we attempted to overcome this problem by only looking at prescriptions with 50 DDDs, it could still be that some of these prescriptions are prescribed for respiratory tract infections or other infections and not for the treatment of acne. Combined oral contraceptives could possibly have been prescribed for contraception only, although this is not recommended for the combination cyproterone and oestrogen. In this study we only included combined oral contraceptives (cyproterone and oestrogen) that are licensed for treatment of moderate to severe acne. Other oral contraceptives with anti-androgenic properties that are not licensed for use in acne, but that could still be used for acne treatment, were not included in the study. A treatment course was defined as the period covering all filled prescriptions of the same drug with less than 365 days between the dispensing days. This definition is a broad definition and will contribute to higher amounts of tetracyclines per treatment course compared with a stricter definition of fewer days between the dispensing days. In our data we observed that many patients had gaps of some months after the 3 months supply of drugs would have been finished and before a new prescription was filled. Due to risk of druginduced photosensitivity, many patients choose to stop treatment with systemic tetracyclines over the summer, which can lead to a gap between filled prescriptions of several months. Also, lack of compliance or relapse of the disease can contribute to gaps between dispensing dates. In this study we wanted to estimate the amount of systemic tetracyclines dispensed per acne episode, and we thereby chose the 365 day break to include relapses of the disease in the same treatment course. Finally, we did not include any information about use of topical retinoid in our study. Treatment with short-term oral antibiotics in combination with topical retinoid and/or benzoyl peroxide is recommended for moderate to severe acne, and can be a way to reduce the use of long-term antibiotics.
Conclusions
Increased prescribing of systemic tetracyclines to treat acne in general, and prolonged use of systemic tetracyclines in patients who later switch to isotretinoin, suggest that patients should be referred to a dermatologist at an earlier stage and consider treatment with isotretinoin to reduce the use of systemic tetracyclines. However, precautions must be taken when treating women with isotretinoin.
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